Section Arrow
ZBIO.NASDAQ
- Zenas Biopharma Inc.
Quotes are at least 15-min delayed:2025/07/25 20:38 EDT
Regular Hours
Last
 15.66
-0.66 (-4.04%)
Day High 
16.5 
Prev. Close
16.32 
1-M High
16.67 
Volume 
164.37K 
Bid
15
Ask
16.99
Day Low
15.14 
Open
16 
1-M Low
8.91 
Market Cap 
682.73M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 13.69 
20-SMA 11.9 
50-SMA 10.94 
52-W High 26.2508 
52-W Low 5.83 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.89/-3.28
Enterprise Value
682.95M
Balance Sheet
Book Value Per Share
6.80
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
5.00M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0596+0.0056+10.37%-- 
ABPAbpro Holdings Inc0.3154+0.0493+18.53%-- 
PHIOPhio Pharmaceuticals Corp2.74+0.23+9.16%0.01PE
TNFATNF Pharmaceuticals Inc.0.1168-0.0152-11.52%-- 
IOVAIovance Biotherapeutics3.13-0.16-4.86%-- 
Quotes are at least 15-min delayed:2025/07/25 20:38 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.